3,000 Participants Added to Trials for Experimental COVID-19 Treatment

A vial of the drug remdesivir is visually inspected at a Gilead manufacturing site in March 2020. Gilead Sciences via AP

Gilead Sciences has increased the number of patients involved in two trials for its experimental COVID-19 treatment remdesivir.

A trial looking at remdesivir in patients with severe cases of COVID-19 upped enrollment from 400 to 2,400 and added some patients on ventilators. Another trial looking at remdesivir in patients with moderate COVID-19 cases increased enrollment from 600 to 1,600.